CD19 CAR (FMC63 scFv) Cellular Immunogenicity Flow Analysis Kit, anti‑human, REAfinity®

The CD19 CAR (FMC63 scFv) Cellular Immunogenicity Flow Analysis Kit, anti‑human, REAfinity has been developed for the fast and easy detection of antigen–reactive T cells by intra- and extracellular staining of activation markers and cytokines. The use of 96-well cell culture plates enables the processing and analysis of multiple samples in parallel. Moreover, it also allows pooling of multiple samples to increase assay sensitivity. The kit contains antibodies for the identification of CD4+ and CD8+ T cells, the exclusion of monocytes and B cells, as well as the stainin

... read more
qualityAssuranceSatisfaction
guaranteed
more »
Specifications for CD19 CAR (FMC63 scFv) Cellular Immunogenicity Flow Analysis Kit, anti‑human, REAfinity®
Overview

The CD19 CAR (FMC63 scFv) Cellular Immunogenicity Flow Analysis Kit, anti‑human, REAfinity has been developed for the fast and easy detection of antigen–reactive T cells by intra- and extracellular staining of activation markers and cytokines. The use of 96-well cell culture plates enables the processing and analysis of multiple samples in parallel. Moreover, it also allows pooling of multiple samples to increase assay sensitivity. The kit contains antibodies for the identification of CD4+ and CD8+ T cells, the exclusion of monocytes and B cells, as well as the staining of activation markers and cytokines. Furthermore, a positive control (CytoStim), a live/dead marker (Viobility 405/452 Fixable Dye), Brefeldin A, and reagents for the fixation and permeabilization of cells after stimulation (Inside Fix and Inside Perm) are included. The optimized antibody panel and protocol ensure a comprehensive and efficient analysis of antigen-reactive T cells. The kit contains recombinantly engineered REAfinity Antibodies. REAfinity Antibodies provide superior lot-to-lot consistency and purity compared to mouse or rat hybridoma-derived monoclonal antibodies. They have been designed to carry a mutated Fc part and do not require an FcR blocking step. Furthermore, REAfinity Antibodies are all based on human IgG1 and require only one common isotype control.

Detailed product information
Background information

The CD19 CAR (FMC63 ScFv) Cellular Immunogenicity Flow Analysis Kit, anti-human, REAfinity is designed to evaluate whether the FMC63 single‑chain variable fragment (scFv) used in CD19 CAR T cells induces T cell activation, thereby indicating the potential for anti-CD19 CAR (FMC63 ScFv) immune responses. The FMC63 scFv is an ectodomain commonly incorporated into CAR constructs that target B cells via CD19. Because FMC63 scFv possesses immunogenic potential, it has been widely used to assess immune responses directed against CAR T cells. In this assay, both CD4+ and CD8+ T cells reactive to the FMC63 scFv can be detected. This is accomplished by incubating peripheral blood mononuclear cells (PBMCs) with a pool of 15‑mer peptides overlapping by 11 amino acids, which together span the entire FMC63 scFv sequence. The peptides are taken up, processed, and presented as antigenic peptides to T cells via major histocompatibility complex (MHC) molecules. T cells that recognize their cognate peptides become activated, and this activation is detected by measuring the expression of CD154, interferon‑γ (IFN‑γ), and tumor necrosis factor‑α (TNF‑α).

Applications
  • Rapid detection and immune monitoring of CD4+ and CD8+ T cells reactive towards CD19 CAR (FMC63 Fv containing) T cells
  • Phenotypical characterization of activated T cells after stimulation with PepTivator Peptide Pools by flow cytometry

Product data and images for CD19 CAR (FMC63 scFv) Cellular Immunogenicity Flow Analysis Kit, anti‑human, REAfinity®
Figure 1

Example of pre‑gating strategy to identify total CD3+ T cells, CD4+ T cells, and CD8+ T cells. Gating on total viable CD3+ T cells (Figure 3D) allows to determine cell counts and frequencies of total CD3+ reactive T cells. Gating on total viable CD4+ T cells (Figure 3E) allows to determine cell counts and frequencies of total CD4+ reactive T cells. Gating on total viable CD8+ T cells (Figure 3E) allows to determine cell counts and frequencies of total CD8+ reactive T cells

Resources for CD19 CAR (FMC63 scFv) Cellular Immunogenicity Flow Analysis Kit, anti‑human, REAfinity®
Certificates

To access a Safety Data Sheet for a hazardous product or component in English or Swedish language, follow the link below and enter the catalog number of the product.

Please note, that the Safety Data Sheet has a cover sheet only in English language.

Should you wish a Safety Data Sheet (SDS) in other languages than English or Swedish, please contact Technical Support.

Get Safety Data Sheet

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?